ClinicalTrials.gg
CompletedNCT01254292Updated Sep 25, 2017Results posted

LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study

A Phase 3 interventional study of Levonorgestrel IUD (LCS, BAY86-5028) and Yasmin (EE30/DRSP, BAY86-5131) in Contraception, sponsored by Bayer. Completed at 94 sites in 5 countries. Open to female participants aged 18 Years to 29 Years. Per ClinicalTrials.gov, last updated 2017-09-25.

Sponsored by Bayer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
567
Allocation
Randomized
Ages
18 Years to 29 Years
Sex
Female
01

Study summary

The primary objective of this study is to evaluate user satisfaction and tolerability in young women (18-29 years of age) using the LCS12 compared with young women using a COC (Yasmin) over a period of 18 months. Subjects in the LCS12 arm will be offered continued use of LCS12 for the full, intended duration of use (up to 3 years) by continuing in a optional, extension phase. Safety data only will be collected during the extension phase of the study.

Secondary objectives are to observe the tolerability, discontinuation rates, adverse event profiles, occurrences of unintended pregnancies (including calculation of Pearl Index [PI]), and bleeding profiles with the two birth-control methods. Additionally, data on missed tablets in the combined oral contraceptive (COC) group, and intrauterine delivery system (IUS) expulsions in the LCS12 group will be recorded. In the LCS12 group, physician satisfaction with the IUS inserter, evaluation of the visibility and texture of the removal threads, and evaluation of the visibility of the LCS12 on ultrasound (in a subset of subjects) will be collected. Finally, in the COC group, information will be collected on the psychosocial impact of missed or delayed pill intake.

02

Conditions studied

  • Contraception
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 29 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has signed and dated the Form (ICF).
  • The subject is generally healthy, requesting , and is between 18 and 29 years of age (inclusive) at Screening.
  • In the opinion of the investigator, the subject is

    • in good health;
    • without uterine conditions that would preempt insertion of LCS12;
    • without conditions/history that would contraindicate the use of oral contraceptives.
  • Subject has normal or clinically insignificant cervical smear (ie, one that does not require further follow up). A cervical smear must be taken at the Screening Visit or a documented normal result has to have been obtained within 6 months of Screening. Subjects with atypical squamous cells of undetermined significance (ASCUS) can be included in the study if they have a Human Papilloma Virus (HPV) deoxyribonucleic acid (DNA) test that, according to the standards of the local laboratory, is negative for high-risk HPV.
  • As determined by subject's history, subject has regular (ie, endogenous cyclicity without hormonal contraceptive use) menstrual cycles (length of cycle 21-35 days).
  • Subject is willing and able to attend the scheduled study visits and to comply with the study procedures.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or current lactation (less than 6 weeks since vaginal or Cesarean delivery or abortion). Note: Postpartum LCS12 insertions should be postponed until the uterus is fully involuted, and not earlier than 6 weeks after delivery. If involution is substantially delayed, the investigator should consider waiting until 12 weeks postpartum.
  • Infected abortion or postpartum endometritis within 3 months prior to the Screening Visit (Visit 1)
  • Chronic, daily use of drugs that may increase serum potassium levels, such as nonsteroidal anti-inflammatory drugs (NSAIDs, eg. ibuprofen and naproxen), potassium-sparing diuretics (eg. spironolactone), potassium supplementation, angiotensin converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists, aldosterone antagonists, and heparin.
  • Abnormal uterine bleeding of unknown origin/undiagnosed abnormal genital bleeding
  • Any genital infection (until successfully treated)
  • Abnormal cervical smear result (see inclusion criteria)
  • Acute, current or history of recurrent pelvic inflammatory disease
  • Congenital or acquired uterine anomaly or any distortion of the uterine cavity (eg, by fibroids) that, in the opinion of the investigator, would cause problems during insertion, retention, or removal of LCS12.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
567 participants (actual)

Study arms

  • Experimental
    LCS12 (Skyla, BAY86-5028)

    Participants received LCS12 (low dose levonorgestrel \[LNG\] intrauterine delivery system \[IUS\]) with an initial in vitro release rate of 12 μg LNG per day for 18 months with optional extension to 36 months

    Drug: Levonorgestrel IUD (LCS, BAY86-5028)

  • Active comparator
    EE30/DRSP (Yasmin, BAY86-5131)

    Participants received combined oral contraceptive (COC) tablet Yasmin containing 30 μg ethinyl estradiol (EE) and 3 mg drospirenone (DRSP) for 18 months/19 cycles

    Drug: Yasmin (EE30/DRSP, BAY86-5131)

Interventions

  • DrugLevonorgestrel IUD (LCS, BAY86-5028)

    LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.

  • DrugYasmin (EE30/DRSP, BAY86-5131)

    Drug page: Drospirenone and ethinyl estradiol combination

    Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.

06

What researchers measure

Primary outcomes

  1. Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF)

    Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.

    Time frame: At 18 months

Secondary outcomes

  1. Overall Satisfaction Rating by the 5-point Likert Item at 6 Months

    Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.

    Time frame: At 6 months

  2. Overall Satisfaction Rating by the 5-point Likert Item at 12 Months

    Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.

    Time frame: At 12 months

  3. Overall Satisfaction Rating by the 5-point Likert Item at 18 Months

    Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.

    Time frame: At 18 months

  4. Overall Satisfaction Rating by the 5-point Likert Item at End of Study (EOS)

    Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question. The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

    Time frame: At 18 months/EOS

  5. Overall Satisfaction Rate at 6 Months (LOCF)

    Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.

    Time frame: At 6 months

  6. Overall Satisfaction Rate at 12 Months (LOCF)

    Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.

    Time frame: At 12 months

  7. User Satisfaction - Acceptability of the Administration of Study Treatment

    The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

    Time frame: At 18 months/EOS

  8. User Satisfaction - Choices Upon Completion of the Study

    The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

    Time frame: At 18 months/EOS

  9. User Satisfaction - Amount of Menstrual Bleeding

    The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

    Time frame: At 18 months/EOS

  10. User Satisfaction - Satisfaction With Menstrual Bleeding Pattern

    The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

    Time frame: At 18 months/EOS

  11. User Satisfaction - Frequency of Experiencing Unexpected Bleeding

    The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

    Time frame: At 18 months/EOS

  12. User Satisfaction - Satisfaction With Menstrual Bleeding Absence

    The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

    Time frame: At 18 months/EOS

  13. User Satisfaction - Comparison of Menstrual Pain Intensity Between Now and Before Treatment

    The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

    Time frame: At 18 months/EOS

  14. User Satisfaction - Rating of Usual Menstrual Pain Intensity

    The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

    Time frame: At 18 months/EOS

  15. EVAPIL-R Scores at Screening - Composite Score

    The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.

    Time frame: At screening

  16. EVAPIL-R Scores at Screening - Bother Score

    The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, , with higher values indicating more severe symptoms/less tolerability.

    Time frame: At screening

  17. EVAPIL-R Scores at 6 Months

    The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.

    Time frame: At 6 months

  18. EVAPIL-R Scores at 12 Months - Bother Score

    The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.

    Time frame: At 12 months

  19. EVAPIL-R Scores at 12 Months - Composite Score

    The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.

    Time frame: At 12 months

  20. EVAPIL-R Scores at 18 Months/EOS

    The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability. The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

    Time frame: At 18 months/EOS

  21. Cumulative Drop-out Rate

    The drop-out rate is the amount of participants that could not complete the study for various reasons. Discontinuation rates due to the following reasons and overall discontinuations were calculated: • LCS12 expulsions • Bleeding pattern alterations • Bleeding pattern alterations with increased bleeding (amount) • Bleeding pattern alterations with decreased bleeding (amount) • Adverse Events The analyses described above were also done by parity. Furthermore, overall discontinuation rates were analyzed by Kaplan-Meier analyses and presented as cumulative half-yearly drop-out rates.

    Time frame: Up to 6, 12, 18, 24 and 36 months

  22. Pearl Index (PI)

    The Pearl Index was defined as the number of pregnancies per 100 woman years (WYs). Given the assumption that the number of pregnancies follows a Poisson distribution, the Pearl Index thus is the mean of this distribution.

    Time frame: Up to 18, 24, 36 months

  23. Compliance Rate for Yasmin Pill Intake

    Time frame: Up to 18 months

  24. User Satisfaction - Acceptability of the Administration of Study Treatment

    The degree of user satisfaction was assessed at the end-of-study visit using an eight item questionnaire. One of the items assessed was acceptability of study treatment which was categorized into the following: acceptable without I/D, acceptable with some I/D, not acceptable with moderate I/D, and not acceptable with extreme I/D.

    Time frame: At 6 months

  25. User Satisfaction - Acceptability of the Administration of Study Treatment

    The degree of user satisfaction was assessed at the end-of-study visit using an eight item questionnaire. One of the items assessed was acceptability of study treatment which was categorized into the following: acceptable without I/D, acceptable with some I/D, not acceptable with moderate I/D, and not acceptable with extreme I/D.

    Time frame: At 12 months

Other outcomes

  1. Cumulative Number of Participants With Partial or Total Expulsion

    Total expulsion is confirmed if the IUS is observed in the vagina, the IUS is not shown in the uterine cavity by ultrasound, and / or the subject confirms that the system was expelled. Partial expulsion is diagnosed if the IUS can be partially seen in the vagina or is displaced in the cervical canal.

    Time frame: Up to 18, 24, 36 months

  2. Investigator's Evaluation of Successful IUS Insertion Procedure

    Time frame: Up to 18 months

  3. Participants' Evaluation of Pain During Successful IUS Insertion Procedure

    Time frame: Up to 18 months

  4. Investigator's Evaluation of IUS Removal Procedure

    Time frame: Up to 36 months

  5. Participants' Evaluation of Pain During IUS Removal Procedure

    Time frame: Up to 36 months

07

Results

Posted Apr 7, 2014

Participant flow

The study was conducted in 42 centers across 4 countries in Austria, Belgium, Germany and United States.

Comparative Phase
Participant flow — Comparative Phase
MilestoneLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Started282285
Participants received treatment279281
Completed227204
Not completed5581
Withdrew: Adverse event2525
Withdrew: Lost to follow-up321
Withdrew: Pregnancy26
Withdrew: Withdrawal by subject2021
Withdrew: Protocol violation12
Withdrew: Wish for pregnancy46
LCS12 Extension Phase
Participant flow — LCS12 Extension Phase
MilestoneLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Started2000
Completed1630
Not completed370
Withdrew: Wish for pregnancy140
Withdrew: Adverse event90
Withdrew: Withdrawal by subject70
Withdrew: Other unknown40
Withdrew: Pregnancy20
Withdrew: Lost to follow-up10

Outcome measures

PrimaryOverall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF)

Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.

Time frame:
At 18 months
Reported as:
Number · Percentage of participants
Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF)
Percentage of participantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF)82.181.9
Statistical analysis
  • LCS12 (Skyla, BAY86-5028) · Single proportion: 82.1 · 95% CI 77.1 to 86.5Clopper Pearson Confidence Interval
  • EE30/DRSP (Yasmin, BAY86-5131) · Single proportion: 81.9 · 95% CI 76.7 to 86.4Clopper Pearson Confidence Interval
SecondaryOverall Satisfaction Rating by the 5-point Likert Item at 6 Months

Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.

Time frame:
At 6 months
Reported as:
Number · Percentage of participants
Overall Satisfaction Rating by the 5-point Likert Item at 6 Months
Percentage of participantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Very Satisfied60.448.1
Satisfied27.535.8
Neither satisfied nor dissatisfied7.39.6
Dissatisfied1.86.2
Very Dissatisfied2.90.4
SecondaryOverall Satisfaction Rating by the 5-point Likert Item at 12 Months

Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.

Time frame:
At 12 months
Reported as:
Number · Percentage of participants
Overall Satisfaction Rating by the 5-point Likert Item at 12 Months
Percentage of participantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Very Satisfied66.845.0
Satisfied22.944.1
Neither satisfied nor dissatisfied5.95.9
Dissatisfied4.33.8
Very Dissatisfied0.01.3
SecondaryOverall Satisfaction Rating by the 5-point Likert Item at 18 Months

Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.

Time frame:
At 18 months
Reported as:
Number · Percentage of participants
Overall Satisfaction Rating by the 5-point Likert Item at 18 Months
Percentage of participantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Very Satisfied64.352.5
Satisfied25.137.8
Neither satisfied nor dissatisfied6.46.9
Dissatisfied3.02.8
Very Dissatisfied1.30.0
SecondaryOverall Satisfaction Rating by the 5-point Likert Item at End of Study (EOS)

Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question. The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

Time frame:
At 18 months/EOS
Reported as:
Number · Percentage of participants
Overall Satisfaction Rating by the 5-point Likert Item at End of Study (EOS)
Percentage of participantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Very Satisfied58.646.6
Satisfied23.535.1
Neither satisfied nor dissatisfied8.69.6
Dissatisfied5.67.6
Very Dissatisfied3.71.2
SecondaryOverall Satisfaction Rate at 6 Months (LOCF)

Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.

Time frame:
At 6 months
Reported as:
Number · Percentage of participants
Overall Satisfaction Rate at 6 Months (LOCF)
Percentage of participantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Overall Satisfaction Rate at 6 Months (LOCF)87.983.8
SecondaryOverall Satisfaction Rate at 12 Months (LOCF)

Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting "1. Very satisfied" or "2. Satisfied" for the above question.

Time frame:
At 12 months
Reported as:
Number · Percentage of participants
Overall Satisfaction Rate at 12 Months (LOCF)
Percentage of participantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Overall Satisfaction Rate at 12 Months (LOCF)84.383.8
SecondaryUser Satisfaction - Acceptability of the Administration of Study Treatment

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

Time frame:
At 18 months/EOS
Reported as:
Number · Participants
User Satisfaction - Acceptability of the Administration of Study Treatment
ParticipantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Acc. without inconvenience/discomfort153186
Acc. with some inconv/discomfort8746
Not acc. with moderate inconv./discomf.1115
Not acc. with extreme inconv./discomf123
SecondaryUser Satisfaction - Choices Upon Completion of the Study

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

Time frame:
At 18 months/EOS
Reported as:
Number · Participants
User Satisfaction - Choices Upon Completion of the Study
ParticipantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Continue with study treatment174122
Use a different hormonal contraceptive3451
Use a different contraceptive method1727
Discont. use of all types of contracept.614
No need for contraceptive at this time512
Undecided2722
SecondaryUser Satisfaction - Amount of Menstrual Bleeding

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

Time frame:
At 18 months/EOS
Reported as:
Number · Participants
User Satisfaction - Amount of Menstrual Bleeding
ParticipantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Decreased8035
Not Changed163207
Increased178
SecondaryUser Satisfaction - Satisfaction With Menstrual Bleeding Pattern

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

Time frame:
At 18 months/EOS
Reported as:
Number · Participants
User Satisfaction - Satisfaction With Menstrual Bleeding Pattern
ParticipantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Very satisfied10191
Somewhat satisfied6584
Neither satisfied nor dissatisfied4868
Dissatisfied194
Very dissatisfied101
Not applicable202
SecondaryUser Satisfaction - Frequency of Experiencing Unexpected Bleeding

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

Time frame:
At 18 months/EOS
Reported as:
Number · Participants
User Satisfaction - Frequency of Experiencing Unexpected Bleeding
ParticipantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Never145219
Seldom9225
Often175
Very Often91
SecondaryUser Satisfaction - Satisfaction With Menstrual Bleeding Absence

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

Time frame:
At 18 months/EOS
Reported as:
Number · Participants
User Satisfaction - Satisfaction With Menstrual Bleeding Absence
ParticipantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Very satisfied966
Somewhat satisfied180
Neither satisfied nor dissatisfied148
Dissatisfied10
Very dissatisfied10
SecondaryUser Satisfaction - Comparison of Menstrual Pain Intensity Between Now and Before Treatment

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

Time frame:
At 18 months/EOS
Reported as:
Number · Participants
User Satisfaction - Comparison of Menstrual Pain Intensity Between Now and Before Treatment
ParticipantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Decreased11861
Not changed102169
Increased3917
SecondaryUser Satisfaction - Rating of Usual Menstrual Pain Intensity

The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

Time frame:
At 18 months/EOS
Reported as:
Number · Participants
User Satisfaction - Rating of Usual Menstrual Pain Intensity
ParticipantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
None12482
Mild7892
Moderate4367
Severe168
SecondaryEVAPIL-R Scores at Screening - Composite Score

The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.

Time frame:
At screening
Reported as:
Mean · Scores on a scale
EVAPIL-R Scores at Screening - Composite Score
Scores on a scaleLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
EVAPIL-R Scores at Screening - Composite Score0.9386 ± 0.80360.8846 ± 0.8231
SecondaryEVAPIL-R Scores at Screening - Bother Score

The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, , with higher values indicating more severe symptoms/less tolerability.

Time frame:
At screening
Reported as:
Mean · Scores on a scale
EVAPIL-R Scores at Screening - Bother Score
Scores on a scaleLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
EVAPIL-R Scores at Screening - Bother Score0.5569 ± 0.44510.5188 ± 0.4406
SecondaryEVAPIL-R Scores at 6 Months

The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.

Time frame:
At 6 months
Reported as:
Mean · Scores on a scale
EVAPIL-R Scores at 6 Months
Scores on a scaleLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Composite score1.3187 ± 0.98881.1537 ± 0.9947
Bother score0.7364 ± 0.49400.6550 ± 0.5148
SecondaryEVAPIL-R Scores at 12 Months - Bother Score

The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.

Time frame:
At 12 months
Reported as:
Mean · Scores on a scale
EVAPIL-R Scores at 12 Months - Bother Score
Scores on a scaleLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
EVAPIL-R Scores at 12 Months - Bother Score0.7789 ± 0.51200.6015 ± 0.4663
SecondaryEVAPIL-R Scores at 12 Months - Composite Score

The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.

Time frame:
At 12 months
Reported as:
Mean · Scores on a scale
EVAPIL-R Scores at 12 Months - Composite Score
Scores on a scaleLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
EVAPIL-R Scores at 12 Months - Composite Score1.4022 ± 1.01261.0535 ± 0.8698
SecondaryEVAPIL-R Scores at 18 Months/EOS

The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability. The 18-month Treatment Visit served as the End-of-Study (EOS) Visit for participant in the COC group and LCS12 participant who did not enter the Extension Phase.

Time frame:
At 18 months/EOS
Reported as:
Mean · Scores on a scale
EVAPIL-R Scores at 18 Months/EOS
Scores on a scaleLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Composite score1.4804 ± 1.19261.0246 ± 0.9546
Bother score0.8113 ± 0.57650.5908 ± 0.4836
SecondaryCumulative Drop-out Rate

The drop-out rate is the amount of participants that could not complete the study for various reasons. Discontinuation rates due to the following reasons and overall discontinuations were calculated: • LCS12 expulsions • Bleeding pattern alterations • Bleeding pattern alterations with increased bleeding (amount) • Bleeding pattern alterations with decreased bleeding (amount) • Adverse Events The analyses described above were also done by parity. Furthermore, overall discontinuation rates were analyzed by Kaplan-Meier analyses and presented as cumulative half-yearly drop-out rates.

Time frame:
Up to 6, 12, 18, 24 and 36 months
Reported as:
Number · Percentage of participants
Cumulative Drop-out Rate
Percentage of participantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Up to 6 months7.5311.39
Up to 12 months13.2621.71
Up to 18 months18.6427.40
Up to 24 months30.85NA
Up to 36 months33.34NA
SecondaryPearl Index (PI)

The Pearl Index was defined as the number of pregnancies per 100 woman years (WYs). Given the assumption that the number of pregnancies follows a Poisson distribution, the Pearl Index thus is the mean of this distribution.

Time frame:
Up to 18, 24, 36 months
Reported as:
Mean · Pregnancies per 100 women years
Pearl Index (PI)
Pregnancies per 100 women yearsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Pearl index up to 18 months0.57 (0.07 to 2.05)1.82 (0.67 to 3.97)
Pearl index up to 24 months0.67 (0.14 to 1.95)NA (NA to NA)
Pearl index up to 36 months0.65 (0.18 to 1.67)NA (NA to NA)
SecondaryCompliance Rate for Yasmin Pill Intake
Time frame:
Up to 18 months
Reported as:
Number · Percentage of participants
Compliance Rate for Yasmin Pill Intake
Percentage of participantsEE30/DRSP (Yasmin, BAY86-5131)
Missing2.8
Compliance <=75%2.1
Compliance >75%95.0
Other pre-specifiedCumulative Number of Participants With Partial or Total Expulsion

Total expulsion is confirmed if the IUS is observed in the vagina, the IUS is not shown in the uterine cavity by ultrasound, and / or the subject confirms that the system was expelled. Partial expulsion is diagnosed if the IUS can be partially seen in the vagina or is displaced in the cervical canal.

Time frame:
Up to 18, 24, 36 months
Reported as:
Number · Participants
Cumulative Number of Participants With Partial or Total Expulsion
ParticipantsLCS12 (Skyla, BAY86-5028)
Partial expulsion up to 18 months0
Total expulsion up to 18 months0
Partial expulsion up to 24 months1
Total expulsion up to 24 months0
Partial expulsion up to 36 months1
Total expulsion up to 36 months0
Other pre-specifiedInvestigator's Evaluation of Successful IUS Insertion Procedure
Time frame:
Up to 18 months
Reported as:
Number · Participants
Investigator's Evaluation of Successful IUS Insertion Procedure
ParticipantsLCS12 (Skyla, BAY86-5028)
Easy247
Slightly difficult31
Very difficult1
Other pre-specifiedParticipants' Evaluation of Pain During Successful IUS Insertion Procedure
Time frame:
Up to 18 months
Reported as:
Number · Participants
Participants' Evaluation of Pain During Successful IUS Insertion Procedure
ParticipantsLCS12 (Skyla, BAY86-5028)
None49
Mild125
Moderate80
Severe25
Other pre-specifiedInvestigator's Evaluation of IUS Removal Procedure
Time frame:
Up to 36 months
Reported as:
Number · Participants
Investigator's Evaluation of IUS Removal Procedure
ParticipantsLCS12 (Skyla, BAY86-5028)
Easy252
Slightly difficult11
Very difficult4
Other pre-specifiedParticipants' Evaluation of Pain During IUS Removal Procedure
Time frame:
Up to 36 months
Reported as:
Number · Participants
Participants' Evaluation of Pain During IUS Removal Procedure
ParticipantsLCS12 (Skyla, BAY86-5028)
None136
Mild96
Moderate30
Severe5
SecondaryUser Satisfaction - Acceptability of the Administration of Study Treatment

The degree of user satisfaction was assessed at the end-of-study visit using an eight item questionnaire. One of the items assessed was acceptability of study treatment which was categorized into the following: acceptable without I/D, acceptable with some I/D, not acceptable with moderate I/D, and not acceptable with extreme I/D.

Time frame:
At 6 months
Reported as:
Number · Participants
User Satisfaction - Acceptability of the Administration of Study Treatment
ParticipantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Acc. without inconvenience/discomfort163192
Acc. with some inconv/discomfort8748
Not acc. with moderate inconv./discomf.44
Not acc. with extreme inconv./discomf.20
SecondaryUser Satisfaction - Acceptability of the Administration of Study Treatment

The degree of user satisfaction was assessed at the end-of-study visit using an eight item questionnaire. One of the items assessed was acceptability of study treatment which was categorized into the following: acceptable without I/D, acceptable with some I/D, not acceptable with moderate I/D, and not acceptable with extreme I/D.

Time frame:
At 12 months
Reported as:
Number · Participants
User Satisfaction - Acceptability of the Administration of Study Treatment
ParticipantsLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Acc. without inconvenience/discomfort152185
Acc. with some inconv/discomfort7433
Not acc. with moderate inconv./discomf.92
Not acc. with extreme inconv./discomf.10

Adverse events

Collected over From start of treatment until 36 months/EOS visit.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LCS12 (Skyla, BAY86-5028)—22/279 (7.9%)215/279 (77.1%)
EE30/DRSP (Yasmin, BAY86-5131)—5/281 (1.8%)148/281 (52.7%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
Ectopic pregnancyPregnancy, puerperium and perinatal conditions3/2790/281
Ligament ruptureInjury, poisoning and procedural complications2/2790/281
AppendicitisInfections and infestations1/2792/281
AppendicitisInfections and infestations1/2792/281
Basedow's diseaseEndocrine disorders1/2790/281
Colitis ulcerativeGastrointestinal disorders1/2790/281
Femoral herniaGastrointestinal disorders1/2790/281
LacerationInjury, poisoning and procedural complications1/2790/281
Ligament ruptureInjury, poisoning and procedural complications1/2790/281
ExostosisMusculoskeletal and connective tissue disorders1/2790/281
Most frequent other events
Showing 10 of 134
Most frequent other events
EventLCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)
DysmenorrhoeaReproductive system and breast disorders48/27926/281
DysmenorrhoeaReproductive system and breast disorders47/27926/281
Cervical dysplasiaReproductive system and breast disorders35/27916/281
AcneSkin and subcutaneous tissue disorders34/2796/281
HeadacheNervous system disorders21/27933/281
HeadacheNervous system disorders26/27932/281
AcneSkin and subcutaneous tissue disorders30/2796/281
Cervical dysplasiaReproductive system and breast disorders25/27916/281
Abdominal painGastrointestinal disorders23/2794/281
CystitisInfections and infestations23/27915/281

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)Total
Mean23.7 ± 3.023.9 ± 3.023.8 ± 3.0
Sex: Female, Male
Sex: Female, Male(Participants)LCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)Total
Female279281560
Male000
Number of births
Number of births(Participants)LCS12 (Skyla, BAY86-5028)EE30/DRSP (Yasmin, BAY86-5131)Total
0216206422
1394988
2192443
3426
4101
08

Study locations

94 sites
  • Visions Clinical Research - Tucson
    Tucson, Arizona 85712, United States
  • Tucson, Arizona 85712, United States
  • Grossmont Center for Clinical Research
    La Mesa, California 91942, United States
  • La Mesa, California 91942, United States
  • Genesis Center for Clinical Research
    San Diego, California 92103, United States
  • San Diego, California 92103, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • San Diego, California 92108, United States
  • Visions Clinical Research
    Boynton Beach, Florida 33472-2952, United States
  • Boynton Beach, Florida 33472-2952, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Boston, Massachusetts 02118, United States
  • Women's Clinic of Lincoln, PC
    Lincoln, Nebraska 68510, United States
  • Lincoln, Nebraska 68510, United States
  • Columbus Center for Women's Health Research
    Columbus, Ohio 43213, United States
  • Columbus, Ohio 43213, United States
  • Oregon Health and Science University
    Portland, Oregon 97239-3011, United States
  • Portland, Oregon 97239-3011, United States
  • Clinical Research of Philadelphia, LLC
    Philadelphia, Pennsylvania 19114, United States
  • Philadelphia, Pennsylvania 19114, United States
  • Advanced Research Associates
    Corpus Christi, Texas 78414, United States
  • Corpus Christi, Texas 78414, United States
  • Seattle Women's: Health, Research, Gynecology
    Seattle, Washington 98105, United States
  • Seattle, Washington 98105, United States
  • Ordination Dr. Schmidl-Amann
    St. Pölten, Niederösterreich 3100, Austria
  • St. Pölten, Niederösterreich 3100, Austria
  • Dr. Max Stiglbauer
    Wiener Neustadt, Niederösterreich 2700, Austria
  • Wiener Neustadt, Niederösterreich 2700, Austria
  • Ordination Dr. Trost
    Voitsberg, Steiermark 8570, Austria
  • Voitsberg, Steiermark 8570, Austria
  • Landeskrankenhaus Bregenz
    Bregenz, Vorarlberg 6900, Austria
  • Bregenz, Vorarlberg 6900, Austria
  • Praxis Dr. Hannes Kahr
    Graz, 8010, Austria
  • Graz, 8010, Austria
  • Dr. Bernhard Svejda
    Klagenfurt, 9020, Austria
  • Klagenfurt, 9020, Austria
  • Ordination Dr. Sator
    Tulln, 3430, Austria
  • Tulln, 3430, Austria
  • Dr. Brigitte Wiesenthal
    Wien, 1070, Austria
  • Wien, 1070, Austria
  • Dr. Wolfgang Bartl
    Wien, 1200, Austria
  • Wien, 1200, Austria
  • Dr. Walter Paulik
    Zeltweg, 8740, Austria
  • Zeltweg, 8740, Austria
  • Dr. Philip Loquet
    Antwerpen, 2018, Belgium
  • Antwerpen, 2018, Belgium
  • Hôpital Erasme/Erasmus Ziekenhuis
    Bruxelles-brussel, 1070, Belgium
  • Bruxelles-brussel, 1070, Belgium
  • Gynaecologen Noord Antwerpen
    Ekeren, 2180, Belgium
  • Ekeren, 2180, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • Gent, 9000, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Leuven, 3000, Belgium
  • Praxis Hr. Dr. A. Soder
    Ettlingen, Baden-Württemberg 76275, Germany
  • Ettlingen, Baden-Württemberg 76275, Germany
  • Praxis Hr. Dr. K. Greven
    Hannover, Niedersachsen 30459, Germany
  • Hannover, Niedersachsen 30459, Germany
  • Praxis Hr. Dr. E. Goeckeler-Leopold
    Geseke, Nordrhein-Westfalen 59590, Germany
  • Geseke, Nordrhein-Westfalen 59590, Germany
  • Evangelisches Krankenhaus Köln Weyertal gGmbH
    Köln, Nordrhein-Westfalen 50931, Germany
  • Köln, Nordrhein-Westfalen 50931, Germany
  • Praxis f. Gynäkologie und Geburtshilfe
    Bernburg, Sachsen-Anhalt 06406, Germany
  • Bernburg, Sachsen-Anhalt 06406, Germany
  • Frauenarztpraxis Dr. Wetzel
    Blankenburg, Sachsen-Anhalt 38889, Germany
  • Blankenburg, Sachsen-Anhalt 38889, Germany
  • Praxis Hr. H. Thelen
    Jessen, Sachsen-Anhalt 06917, Germany
  • Jessen, Sachsen-Anhalt 06917, Germany
  • Praxis Fr. Dr. A. Braune
    Magdeburg, Sachsen-Anhalt 39104, Germany
  • Magdeburg, Sachsen-Anhalt 39104, Germany
  • Frauenarztpraxis Dr. Robert Hantschel
    Dippoldiswalde, Sachsen 01744, Germany
  • Dippoldiswalde, Sachsen 01744, Germany
  • Praxis Hr. Dr. U. Kopprasch
    Dresden, Sachsen 01169, Germany
  • Dresden, Sachsen 01169, Germany
  • Frauenarztpraxis Dr. Bernd Pittner
    Leipzig, Sachsen 04207, Germany
  • Leipzig, Sachsen 04207, Germany
  • Praxis Fr. C. Burgkhardt
    Leipzig, Sachsen 04299, Germany
  • Leipzig, Sachsen 04299, Germany
  • Praxis Hr. Dr. D. Rautenberg
    Hamburg, 21073, Germany
  • Hamburg, 21073, Germany
  • Praxis Hr. Dr. K. Peters
    Hamburg, 22159, Germany
  • Hamburg, 22159, Germany
  • Praxis Hr. Dr. K. Buehling
    Hamburg, 22587, Germany
  • Hamburg, 22587, Germany
  • Altai State Medical University
    Barnaul, 656038, Russian Federation
  • Barnaul, 656038, Russian Federation
  • Scientific Center of family health & human reprod. problems
    Irkutsk, 664003, Russian Federation
  • Irkutsk, 664003, Russian Federation
  • Instit. of Motherhood & Childhood care n.a. Gorodkov
    Ivanovo, 153045, Russian Federation
  • Ivanovo, 153045, Russian Federation
  • City Perinatal Center
    Novosibirsk, 630089, Russian Federation
  • Novosibirsk, 630089, Russian Federation
  • Institute of Obsteric & Gyn.
    St. Petersburg, 199034, Russian Federation
  • St. Petersburg, 199034, Russian Federation
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2011 to primary completion in Jan 2013, 24 months.

Results were first posted in Apr 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2010
First posted
Dec 6, 2010
StartActual
Jan 6, 2011
Primary completionActual
Jan 8, 2013
CompletionActual
May 28, 2014
Results first posted
Apr 7, 2014
Last update
Sep 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01254292
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Dec 6, 2010
Start date
Jan 6, 2011
Primary completion
Jan 8, 2013
Completion
May 28, 2014
Results posted
Apr 7, 2014
Last update
Sep 25, 2017

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion